Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 407

1.
2.

Prediction of the anti-inflammatory mechanisms of curcumin by module-based protein interaction network analysis.

Gan Y, Zheng S, Baak JP, Zhao S, Zheng Y, Luo N, Liao W, Fu C.

Acta Pharm Sin B. 2015 Nov;5(6):590-5. doi: 10.1016/j.apsb.2015.09.005. Epub 2015 Oct 21.

3.
4.

Prediction of spontaneous regression of cervical intraepithelial neoplasia lesions grades 2 and 3 by proteomic analysis.

Uleberg KE, Ovestad IT, Munk AC, Brede C, van Diermen B, Gudlaugsson E, Janssen EA, Hjelle A, Baak JP.

Int J Proteomics. 2014;2014:129064. doi: 10.1155/2014/129064. Epub 2014 Jun 15.

5.

Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder.

Mangrud OM, Gudlaugsson E, Skaland I, Tasdemir I, Dalen I, van Diermen B, Baak JP, Janssen EA.

Hum Pathol. 2014 Jul;45(7):1496-503. doi: 10.1016/j.humpath.2014.03.001. Epub 2014 Mar 26.

PMID:
24796506
6.

Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.

Jonsdottir K, Assmus J, Slewa A, Gudlaugsson E, Skaland I, Baak JP, Janssen EA.

PLoS One. 2014 Mar 5;9(3):e90642. doi: 10.1371/journal.pone.0090642. eCollection 2014.

7.

Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder.

Mangrud OM, Waalen R, Gudlaugsson E, Dalen I, Tasdemir I, Janssen EA, Baak JP.

PLoS One. 2014 Jan 7;9(1):e83192. doi: 10.1371/journal.pone.0083192. eCollection 2014.

8.

The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.

Klintman M, Strand C, Ahlin C, Beglerbegovic S, Fjällskog ML, Grabau D, Gudlaugsson E, Janssen EA, Lövgren K, Skaland I, Bendahl PO, Malmström P, Baak JP, Fernö M.

PLoS One. 2013 Dec 4;8(12):e81902. doi: 10.1371/journal.pone.0081902. eCollection 2013.

9.

Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade?

Feng W, Malpica A, Skaland I, Gudlaugsson E, Robboy SJ, Dalen I, Hua K, Zhou X, Baak JP.

PLoS One. 2013 Oct 11;8(10):e75899. doi: 10.1371/journal.pone.0075899. eCollection 2013.

11.

Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family.

Feng W, Malpica A, Robboy SJ, Gudlaugsson E, Hua K, Zhou X, Baak JP.

Int J Gynecol Pathol. 2013 May;32(3):299-306. doi: 10.1097/PGP.0b013e318229adfb.

PMID:
23545579
12.

Diagnostic and prognostic morphometric features in WHO2003 invasive endometrial stromal tumours.

Feng W, Malpica A, Yinhua Y, Janssen E, Gudlaugsson E, Zhou X, Baak JP.

Histopathology. 2013 Apr;62(5):688-94. doi: 10.1111/j.1365-2559.2011.04120.x.

PMID:
23530584
13.

Stages I to II WHO 2003-defined low-grade endometrial stromal sarcoma: how much primary therapy is needed and how little is enough?

Feng W, Hua K, Malpica A, Zhou X, Baak JP.

Int J Gynecol Cancer. 2013 Mar;23(3):488-93. doi: 10.1097/IGC.0b013e318247aa14.

PMID:
23435438
14.

Prognostic indicators in WHO 2003 low-grade endometrial stromal sarcoma.

Feng W, Hua K, Gudlaugsson E, Yu Y, Zhou X, Baak JP.

Histopathology. 2013 Apr;62(5):675-87. doi: 10.1111/j.1365-2559.2011.04115.x. Epub 2013 Feb 21.

PMID:
23425310
15.

Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers.

Jonsdottir K, Janssen SR, Da Rosa FC, Gudlaugsson E, Skaland I, Baak JP, Janssen EA.

PLoS One. 2012;7(11):e48692. doi: 10.1371/journal.pone.0048692. Epub 2012 Nov 7.

16.

Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study.

Munk AC, Ovestad IT, Gudlaugsson E, Løvslett K, Fiane B, van Diermen-Hidle B, Kruse AJ, Skaland I, Janssen EA, Baak JP.

Infect Agent Cancer. 2012 Nov 5;7(1):30. doi: 10.1186/1750-9378-7-30.

17.

Consistent condom use increases the regression rate of cervical intraepithelial neoplasia 2-3.

Munk AC, Gudlaugsson E, Malpica A, Fiane B, Løvslett KI, Kruse AJ, Øvestad IT, Voorhorst F, Janssen EA, Baak JP.

PLoS One. 2012;7(9):e45114. doi: 10.1371/journal.pone.0045114. Epub 2012 Sep 13.

18.

Interaction of epithelial biomarkers, local immune response and condom use in cervical intraepithelial neoplasia 2-3 regression.

Munk AC, Gudlaugsson E, Ovestad IT, Lovslett K, Fiane B, Hidle Bv, Kruse AJ, Skaland I, Janssen EA, Baak JP.

Gynecol Oncol. 2012 Dec;127(3):489-94. doi: 10.1016/j.ygyno.2012.09.010. Epub 2012 Sep 24.

PMID:
23017821
19.

Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer.

Gudlaugsson E, Skaland I, Janssen EA, Smaaland R, Shao Z, Malpica A, Voorhorst F, Baak JP.

Histopathology. 2012 Dec;61(6):1134-44. doi: 10.1111/j.1365-2559.2012.04329.x. Epub 2012 Sep 11.

PMID:
22963617
20.

The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.

Jonsdottir K, Zhang H, Jhagroe D, Skaland I, Slewa A, Björkblom B, Coffey ET, Gudlaugsson E, Smaaland R, Janssen EA, Baak JP.

Breast Cancer Res Treat. 2012 Sep;135(2):381-90. doi: 10.1007/s10549-012-2155-9. Epub 2012 Jul 8.

PMID:
22772381
21.

Prognostic proof and possible therapeutic mechanisms of herbal medicine in patients with metastatic lung and colon cancer.

Baak JP, Gyllenhaal C, Liu L, Guo H, Block KI.

Integr Cancer Ther. 2011 Sep;10(3):NP1-NP11. doi: 10.1177/1534735411421172. Epub 2011 Sep 22.

PMID:
21948133
22.

Vascular proliferation is a prognostic factor in breast cancer.

Arnes JB, Stefansson IM, Straume O, Baak JP, Lønning PE, Foulkes WD, Akslen LA.

Breast Cancer Res Treat. 2012 Jun;133(2):501-10. doi: 10.1007/s10549-011-1785-7. Epub 2011 Sep 27.

PMID:
21947750
23.

Is the improvement of prognosis of patients with metastatic pulmonary adenocarcinoma treated with TCM herbal medicine due to lag time to treatment bias?

Guo H, Liu L, Baak JP.

Integr Cancer Ther. 2011 Sep;10(3):234-9. doi: 10.1177/1534735411418112. Epub 2011 Aug 23.

PMID:
21862517
24.

Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.

Ovestad IT, Vennestrøm U, Andersen L, Gudlaugsson E, Munk AC, Malpica A, Feng W, Voorhorst F, Janssen EA, Baak JP.

Gynecol Oncol. 2011 Nov;123(2):278-83. doi: 10.1016/j.ygyno.2011.07.024. Epub 2011 Aug 10.

PMID:
21835440
25.

From SELDI-TOF MS to protein identification by on-chip elution.

Mæland Nilsen M, Uleberg KE, Janssen EA, Baak JP, Andersen OK, Hjelle A.

J Proteomics. 2011 Nov 18;74(12):2995-8. doi: 10.1016/j.jprot.2011.06.027. Epub 2011 Jul 23.

PMID:
21798383
26.

Discrimination of grade 2 and 3 cervical intraepithelial neoplasia by means of analysis of water soluble proteins recovered from cervical biopsies.

Uleberg KE, Munk AC, Brede C, Gudlaugsson E, van Diermen B, Skaland I, Malpica A, Janssen EA, Hjelle A, Baak JP.

Proteome Sci. 2011 Jun 28;9:36. doi: 10.1186/1477-5956-9-36.

27.

A protein profile study to discriminate CIN lesions from normal cervical epithelium.

Uleberg KE, Munk AC, Skaland I, Furlan C, van Diermen B, Gudlaugsson E, Janssen EA, Malpica A, Feng W, Hjelle A, Baak JP.

Cell Oncol (Dordr). 2011 Oct;34(5):443-50. doi: 10.1007/s13402-011-0047-3. Epub 2011 May 15.

28.

Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma.

Steinbakk A, Malpica A, Slewa A, Skaland I, Gudlaugsson E, Janssen EA, Løvslett K, Fiane B, Kruse AJ, Feng W, Yinhua Y, Baak JP.

Mod Pathol. 2011 Sep;24(9):1262-71. doi: 10.1038/modpathol.2011.75. Epub 2011 May 6.

29.

High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases.

Steinbakk A, Malpica A, Slewa A, Gudlaugsson E, Janssen EA, Arends M, Kruse AJ, Yinhua Y, Feng W, Baak JP.

Cell Oncol (Dordr). 2011 Oct;34(5):457-65. doi: 10.1007/s13402-011-0040-x. Epub 2011 May 6. Erratum in: Cell Oncol (Dordr). 2011 Oct;34(5):509-10.

PMID:
21547578
30.

Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.

Gilje B, Nordgård O, Tjensvoll K, Janssen EA, Søiland H, Smaaland R, Baak JP.

Breast Cancer Res Treat. 2011 Jul;128(1):137-46. doi: 10.1007/s10549-011-1487-1. Epub 2011 Apr 8.

PMID:
21476002
31.

The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3.

Ovestad IT, Gudlaugsson E, Skaland I, Malpica A, Munk AC, Janssen EA, Baak JP.

J Clin Pathol. 2011 Apr;64(4):303-7. doi: 10.1136/jcp.2010.083626.

PMID:
21421698
32.

The prognostic value of the orphan nuclear receptor DAX-1 (NROB1) in node-negative breast cancer.

Zhang H, Slewa A, Janssen E, Skaland I, Yu Y, Gudlaugsson E, Feng W, Kjellevold K, Søiland H, Baak JP.

Anticancer Res. 2011 Feb;31(2):443-9.

PMID:
21378322
33.

Molecular biomarkers in endometrial hyperplasias predict cancer progression.

Steinbakk A, Gudlaugsson E, Aasprong OG, Skaland I, Malpica A, Feng W, Janssen EA, Baak JP.

Am J Obstet Gynecol. 2011 Apr;204(4):357.e1-12. doi: 10.1016/j.ajog.2010.12.007. Epub 2011 Feb 16.

PMID:
21324435
34.

D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients.

Gudlaugsson E, Skaland I, Undersrud E, Janssen EA, Søiland H, Baak JP.

Mod Pathol. 2011 Apr;24(4):502-11. doi: 10.1038/modpathol.2010.199. Epub 2011 Feb 11.

35.

Neoplastic transformation of endocervicosis into an extraovarian mucinous cystadenocarcinoma.

Kruse AJ, Slangen B, Dunselman GA, Pirens T, Bakers FC, Baak JP, de Vijver KV.

Hum Pathol. 2011 May;42(5):743-8. doi: 10.1016/j.humpath.2010.08.017. Epub 2011 Jan 15.

PMID:
21237491
36.

In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant!

Lende TH, Janssen EA, Gudlaugsson E, Voorhorst F, Smaaland R, van Diest P, Søiland H, Baak JP.

J Clin Oncol. 2011 Mar 1;29(7):852-8. doi: 10.1200/JCO.2009.25.0407. Epub 2010 Dec 28.

PMID:
21189388
37.
38.

High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases.

Steinbakk A, Malpica A, Slewa A, Gudlaugsson E, Janssen EA, Arends M, Kruse AJ, Yinhua Y, Feng W, Baak JP.

Anal Cell Pathol (Amst). 2010;33(5):245-55. doi: 10.3233/ACP-CLO-2010-0550.

39.

Biologic profiling of lymph node negative breast cancers by means of microRNA expression.

Janssen EA, Slewa A, Gudlaugsson E, Jonsdottir K, Skaland I, Søiland H, Baak JP.

Mod Pathol. 2010 Dec;23(12):1567-76. doi: 10.1038/modpathol.2010.177. Epub 2010 Sep 3.

40.

Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression.

Øvestad IT, Gudlaugsson E, Skaland I, Malpica A, Kruse AJ, Janssen EA, Baak JP.

Mod Pathol. 2010 Sep;23(9):1231-40. doi: 10.1038/modpathol.2010.109. Epub 2010 May 28.

41.

Patients with clinical/radiological hyperplasia of mammary glands show pathological persistence of temperature of skin points.

Li H, Shen X, Ying J, Zhao L, Jin M, Thu S, Sun C, Voorhorst F, Soiland H, Lende T, Baak JP.

Anticancer Res. 2009 Nov;29(11):4697-702.

42.

LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer.

Janssen EA, Øvestad IT, Skaland I, Søiland H, Gudlaugsson E, Kjellevold KH, Nysted A, Søreide JA, Baak JP.

Cell Oncol. 2009;31(5):335-43. doi: 10.3233/CLO-2009-0479.

43.

Evaluation of 5 different labeled polymer immunohistochemical detection systems.

Skaland I, Nordhus M, Gudlaugsson E, Klos J, Kjellevold KH, Janssen EA, Baak JP.

Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):90-6. doi: 10.1097/PAI.0b013e3181b0eaad.

PMID:
19661787
44.
45.

Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer.

Gudlaugsson E, Skaland I, Janssen EA, van Diest PJ, Voorhorst FJ, Kjellevold K, zur Hausen A, Baak JP.

Breast Cancer Res Treat. 2010 May;121(1):35-40. doi: 10.1007/s10549-009-0442-x. Epub 2009 Jul 1.

PMID:
19568929
46.

Squamous morules are functionally inert elements of premalignant endometrial neoplasia.

Lin MC, Lomo L, Baak JP, Eng C, Ince TA, Crum CP, Mutter GL.

Mod Pathol. 2009 Feb;22(2):167-74. doi: 10.1038/modpathol.2008.146. Epub 2008 Sep 19.

47.

Microsatellite instability and DNA ploidy in colorectal cancer: potential implications for patients undergoing systematic surveillance after resection.

Søreide K, Slewa A, Stokkeland PJ, van Diermen B, Janssen EA, Søreide JA, Baak JP, Kørner H.

Cancer. 2009 Jan 15;115(2):271-82. doi: 10.1002/cncr.24024.

48.

Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.

Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.

Acta Oncol. 2009;48(4):514-21. doi: 10.1080/02841860802620613.

PMID:
19107621
49.

The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study.

Verbruggen MB, van Diest PJ, Baak JP, Broeckaert MA, Kenemans P, Verheijen RH.

Int J Gynecol Pathol. 2009 Jan;28(1):35-40. doi: 10.1097/PGP.0b013e31818131ff.

PMID:
19047910
50.

The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer.

Steinbakk A, Skaland I, Gudlaugsson E, Janssen EA, Kjellevold KH, Klos J, Løvslett K, Fiane B, Baak JP.

Am J Obstet Gynecol. 2009 Jan;200(1):78.e1-8. doi: 10.1016/j.ajog.2008.07.020. Epub 2008 Oct 30.

PMID:
18976730

Supplemental Content

Support Center